279 related articles for article (PubMed ID: 25293517)
1. Invasive fungal infection in patients receiving chemotherapy for hematological malignancy: a multicenter, prospective, observational study in China.
Sun Y; Huang H; Chen J; Li J; Ma J; Li J; Liang Y; Wang J; Li Y; Yu K; Hu J; Jin J; Wang C; Wu D; Xiao Y; Huang X
Tumour Biol; 2015 Feb; 36(2):757-67. PubMed ID: 25293517
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study.
Sun Y; Meng F; Han M; Zhang X; Yu L; Huang H; Wu D; Ren H; Wang C; Shen Z; Ji Y; Huang X
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1117-26. PubMed ID: 25840339
[TBL] [Abstract][Full Text] [Related]
3. Does High-Dose Cytarabine Cause More Fungal Infection in Patients With Acute Myeloid Leukemia Undergoing Consolidation Therapy: A Multicenter, Prospective, Observational Study in China.
Wang L; Hu J; Sun Y; Huang H; Chen J; Li J; Ma J; Li J; Liang Y; Wang J; Li Y; Yu K; Hu J; Jin J; Wang C; Wu D; Xiao Y; Huang X
Medicine (Baltimore); 2016 Jan; 95(4):e2560. PubMed ID: 26825897
[TBL] [Abstract][Full Text] [Related]
4. Neutropenia and invasive fungal infection in patients with hematological malignancies treated with chemotherapy: a multicenter, prospective, non-interventional study in China.
Li Y; Xu W; Jiang Z; Gao Y; Pang Y; Li L; OuYang L; Zhang L; Liu Z; Wang Y; Xiao Y; Huang X
Tumour Biol; 2014 Jun; 35(6):5869-76. PubMed ID: 24664582
[TBL] [Abstract][Full Text] [Related]
5. The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole.
Barreto JN; Beach CL; Wolf RC; Merten JA; Tosh PK; Wilson JW; Hogan WJ; Litzow MR
Am J Hematol; 2013 Apr; 88(4):283-8. PubMed ID: 23460251
[TBL] [Abstract][Full Text] [Related]
6. Invasive fungal infections in AML/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?
Pomares H; Arnan M; Sánchez-Ortega I; Sureda A; Duarte RF
Mycoses; 2016 Aug; 59(8):516-9. PubMed ID: 27027972
[TBL] [Abstract][Full Text] [Related]
7. Posaconazole vs. fluconazole as invasive fungal infection prophylaxis in China: a multicenter, randomized, open-label study.
Shen Y; Huang XJ; Wang JX; Jin J; Hu JD; Yu K; Wu DP; Wang SJ; Yu L; Chen XQ; Liu T; Liang YM; Chen FP; Li Y; Shen ZX
Int J Clin Pharmacol Ther; 2013 Sep; 51(9):738-45. PubMed ID: 23924680
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies.
Kurosawa M; Yonezumi M; Hashino S; Tanaka J; Nishio M; Kaneda M; Ota S; Koda K; Suzuki N; Yoshida M; Hirayama Y; Takimoto R; Torimoto Y; Mori A; Takahashi T; Iizuka S; Ishida T; Kobayashi R; Oda T; Sakai H; Yamamoto S; Takahashi F; Fukuhara T
Int J Hematol; 2012 Dec; 96(6):748-57. PubMed ID: 23111539
[TBL] [Abstract][Full Text] [Related]
9. Micafungin prophylaxis in routine medical practice in adult and pediatric patients with hematological malignancy: a prospective, observational study in France.
El Cheikh J; Ceballos P; Dalle JH; Ducastelle-Leprêtre S; Dulon E; Herbrecht R
Diagn Microbiol Infect Dis; 2019 Jul; 94(3):268-273. PubMed ID: 30842034
[TBL] [Abstract][Full Text] [Related]
10. High incidence of invasive fungal infection during acute myeloid leukemia treatment in a resource-limited country: clinical risk factors and treatment outcomes.
Nganthavee V; Phutthasakda W; Atipas K; Tanpong S; Pungprasert T; Dhirachaikulpanich D; Krithin S; Tanglitanon S; Jutidamronphang W; Owattanapanich W; Chayakulkeeree M; Phikulsod P
Support Care Cancer; 2019 Sep; 27(9):3613-3622. PubMed ID: 31165931
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for breakthrough invasive fungal infection during secondary prophylaxis.
Cornely OA; Böhme A; Reichert D; Reuter S; Maschmeyer G; Maertens J; Buchheidt D; Paluszewska M; Arenz D; Bethe U; Effelsberg J; Lövenich H; Sieniawski M; Haas A; Einsele H; Eimermacher H; Martino R; Silling G; Hahn M; Wacker S; Ullmann AJ; Karthaus M;
J Antimicrob Chemother; 2008 Apr; 61(4):939-46. PubMed ID: 18272515
[TBL] [Abstract][Full Text] [Related]
12. Retrospective study on the incidence and outcome of proven and probable invasive fungal infections in high-risk pediatric onco-hematological patients.
Cesaro S; Tridello G; Castagnola E; Calore E; Carraro F; Mariotti I; Colombini A; Perruccio K; Decembrino N; Russo G; Maximova N; Baretta V; Caselli D
Eur J Haematol; 2017 Sep; 99(3):240-248. PubMed ID: 28556426
[TBL] [Abstract][Full Text] [Related]
13. Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
Busca A; Candoni A; Audisio E; Passera R; Bruno B; Monaco F; Mordini N; Vacca A; Delia M; Aversa F; Pagano L
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2214-2219. PubMed ID: 27667012
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infection in high-risk neutropenic patients in Sweden.
Lundberg J; Höglund M; Björkholm M; Åkerborg Ö
Clin Drug Investig; 2014 Jul; 34(7):483-9. PubMed ID: 24820968
[TBL] [Abstract][Full Text] [Related]
15. Invasive fungal infection following chemotherapy for acute myeloid leukaemia-Experience from a developing country.
Korula A; Abraham A; Abubacker FN; Viswabandya A; Lakshmi KM; Abraham OC; Rupali P; Varghese GM; Michael JS; Srivastava A; Mathews V; George B
Mycoses; 2017 Oct; 60(10):686-691. PubMed ID: 28736936
[TBL] [Abstract][Full Text] [Related]
16. Treatment of invasive fungal infections in high risk hematological patients. The outcome with liposomal amphotericin B is not negatively affected by prior administration of mold-active azoles.
De la Serna J; Jarque I; López-Jiménez J; Fernández-Navarro JM; Gómez V; Jurado M; Pascual A; Serrano J; Romero M; Vallejo C
Rev Esp Quimioter; 2013 Mar; 26(1):64-9. PubMed ID: 23546466
[TBL] [Abstract][Full Text] [Related]
17. Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study.
Bose P; McCue D; Wurster S; Wiederhold NP; Konopleva M; Kadia TM; Borthakur G; Ravandi F; Masarova L; Takahashi K; Estrov Z; Yilmaz M; Daver N; Pemmaraju N; Naqvi K; Rausch CR; Marx KR; Qiao W; Huang X; Bivins CA; Pierce SA; Kantarjian HM; Kontoyiannis DP
Clin Infect Dis; 2021 May; 72(10):1755-1763. PubMed ID: 32236406
[TBL] [Abstract][Full Text] [Related]
18. Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology-oncology patients: a retrospective cohort study.
Kung HC; Johnson MD; Drew RH; Saha-Chaudhuri P; Perfect JR
Cancer Med; 2014 Jun; 3(3):667-73. PubMed ID: 24644249
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics and treatment outcomes of pulmonary invasive fungal infection among adult patients with hematological malignancy in a medical centre in Taiwan, 2008-2013.
Chen CY; Sheng WH; Tien FM; Lee PC; Huang SY; Tang JL; Tsay W; Tien HF; Hsueh PR
J Microbiol Immunol Infect; 2020 Feb; 53(1):106-114. PubMed ID: 29449166
[TBL] [Abstract][Full Text] [Related]
20. Severe infections in children with acute leukemia undergoing intensive chemotherapy can successfully be prevented by ciprofloxacin, voriconazole, or micafungin prophylaxis.
Yeh TC; Liu HC; Hou JY; Chen KH; Huang TH; Chang CY; Liang DC
Cancer; 2014 Apr; 120(8):1255-62. PubMed ID: 24415457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]